{"count": 4, "results": [{"_id": "35405270", "pmid": 35405270, "title": "Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice.", "journal": "Eur J Pharm Sci", "authors": ["Sun H", "Zhou Y", "Ma R", "Zhang J", "Shan J", "Chen Y", "Li X", "Shan E"], "date": "2022-06-01T00:00:00Z", "doi": "10.1016/j.ejps.2022.106182", "meta_date_publication": "2022 Jun 1", "meta_volume": "173", "meta_issue": "", "meta_pages": "106182", "score": 50247.633, "text_hl": "@CHEMICAL_Fluorouracil @CHEMICAL_MESH:D005472 @@@5-Fu@@@ was used in the @CELLLINE_CVCL:C0MU @@@C57BL/6@@@ @SPECIES_10090 @@@mice@@@ to establish the model of CIOM. Our results showed @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Met@@@ could significantly improve @CHEMICAL_Fluorouracil @CHEMICAL_MESH:D005472 @@@5-Fu@@@-induced @<m>DISEASE_Mucositis</m> @DISEASE_MESH:D052016 @@@mucosal damage@@@, apoptosis, ROS and releasing of @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ factors in the tongue tissue. ", "citations": {"NLM": "Sun H, Zhou Y, Ma R, Zhang J, Shan J, Chen Y, Li X, Shan E. Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice. Eur J Pharm Sci. 2022 Jun 1;173():106182. PMID: 35405270", "BibTeX": "@article{35405270, title={Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice.}, author={Sun H and Zhou Y and Ma R and Zhang J and Shan J and Chen Y and Li X and Shan E}, journal={Eur J Pharm Sci}, volume={173}, pages={106182}}"}}, {"_id": "31516889", "pmid": 31516889, "pmcid": "PMC6712895", "title": "The Radioprotective Effect of Combination of Melatonin and Metformin on Rat Duodenum Damage Induced by Ionizing Radiation: A Histological Study", "journal": "Adv Biomed Res", "authors": ["Najafi M", "Cheki M", "Hassanzadeh G", "Amini P", "Shabeeb D", "Musa AE"], "date": "2019-08-21T00:00:00Z", "doi": "10.4103/abr.abr_68_19", "meta_date_publication": "2019", "meta_volume": "8", "meta_issue": "", "meta_pages": "51", "score": 50083.83, "text_hl": "Administration of @CHEMICAL_Melatonin @CHEMICAL_MESH:D008550 @@@melatonin@@@ plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could reduce @<m>DISEASE_Mucositis</m> @DISEASE_MESH:D052016 @@@mucositis@@@ in duodenum. ", "citations": {"NLM": "Najafi M, Cheki M, Hassanzadeh G, Amini P, Shabeeb D, Musa AE. The Radioprotective Effect of Combination of Melatonin and Metformin on Rat Duodenum Damage Induced by Ionizing Radiation: A Histological Study Adv Biomed Res. 2019;8():51. PMID: 31516889", "BibTeX": "@article{31516889, title={The Radioprotective Effect of Combination of Melatonin and Metformin on Rat Duodenum Damage Induced by Ionizing Radiation: A Histological Study}, author={Najafi M and Cheki M and Hassanzadeh G and Amini P and Shabeeb D and Musa AE}, journal={Adv Biomed Res}, volume={8}, pages={51}}"}}, {"_id": "29653414", "pmid": 29653414, "title": "New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats.", "journal": "Pharmacol Rep", "authors": ["Samman FS", "Elaidy SM", "Essawy SS", "Hassan MS"], "date": "2018-06-01T00:00:00Z", "doi": "10.1016/j.pharep.2017.11.015", "meta_date_publication": "2018 Jun", "meta_volume": "70", "meta_issue": "3", "meta_pages": "488-496", "score": 50040.84, "text_hl": "Body weights, survival rates, disease activity index (DAI), colonic oxidative stress markers, @GENE_TNF @GENE_24835 @@@tumor necrosis factor (TNF)-alpha@@@ levels, colonic nuclear factor-kappa-B (NF-kappaB) immunohistochemical expression, and the colonic histopathological changes were observed. RESULTS: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ or/and @CHEMICAL_Thioctic_Acid @CHEMICAL_MESH:D008063 @@@alpha-LA@@@ attenuated the severity of the @CHEMICAL_Dextran_Sulfate @CHEMICAL_MESH:D016264 @@@DSS@@@-induced @DISEASE_Colitis @DISEASE_MESH:D003092 @@@colitis@@@ through improving the reductions in body weights, the DAI, the colonic oxidative stress markers, @GENE_TNF @GENE_24835 @@@TNF-alpha@@@, and NF-kappaB levels, and the morphological @<m>DISEASE_Mucositis</m> @DISEASE_MESH:D052016 @@@mucosal damage@@@ scores. ", "citations": {"NLM": "Samman FS, Elaidy SM, Essawy SS, Hassan MS. New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats. Pharmacol Rep. 2018 Jun;70(3):488-496. PMID: 29653414", "BibTeX": "@article{29653414, title={New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats.}, author={Samman FS and Elaidy SM and Essawy SS and Hassan MS}, journal={Pharmacol Rep}, volume={70}, number={3}, pages={488-496}}"}}, {"_id": "31588998", "pmid": 31588998, "title": "PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.", "journal": "Cochrane Database Syst Rev", "authors": ["Roncolato F", "Lindemann K", "Willson ML", "Martyn J", "Mileshkin L"], "date": "2019-10-07T00:00:00Z", "doi": "10.1002/14651858.CD012160.pub2", "meta_date_publication": "2019 Oct 7", "meta_volume": "10", "meta_issue": "10", "meta_pages": "CD012160", "score": 50018.293, "text_hl": "We identified five ongoing studies on the effects of PI3K and @GENE_AKT1 @GENE_207 @@@AKT@@@ inhibitors, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and dual @GENE_MTOR @GENE_2475 @@@mTOR@@@ inhibitors.For first-line therapy, an mTOR inhibitor-containing regimen may worsen progression-free survival (HR 1.43, 95% CI 1.06 to 1.93; 1 study, 231 @SPECIES_9606 @@@participants@@@; low-certainty evidence), while for second/third-line therapy, an mTOR inhibitor probably improves progression-free survival compared to chemotherapy or endocrine therapy (HR 0.53, 95% CI 0.31 to 0.91; 1 study, 95 @SPECIES_9606 @@@participants@@@; moderate-certainty evidence). ", "citations": {"NLM": "Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. PMID: 31588998", "BibTeX": "@article{31588998, title={PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.}, author={Roncolato F and Lindemann K and Willson ML and Martyn J and Mileshkin L}, journal={Cochrane Database Syst Rev}, volume={10}, number={10}, pages={CD012160}}"}}]}